Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Jan 16;8(4):LMT18.
doi: 10.2217/lmt-2019-0012.

Immune checkpoints inhibitors rechallenge in non-small-cell lung cancer: different scenarios with different solutions?

Giulio Metro  1 , Diego Signorelli  2
Affiliations
Editorial

Immune checkpoints inhibitors rechallenge in non-small-cell lung cancer: different scenarios with different solutions?

Giulio Metro et al. Lung Cancer Manag. .
No abstract available

Keywords: duration of treatment; immune checkpoint inhibitors; immunotherapy; non-small-cell lung cancer; rechallenge.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure G Metro discloses consultancies from Boehringer Ingelheim and Bristol-Myers Squibb and travel grants from AstraZeneca. D Signorelli discloses a consultancy from AstraZeneca and travel grants from Bristol-Myers Squibb, Merck, Pfizer and Roche. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

References

    1. Toschi L, Rossi S, Finocchiaro G, Santoro A. Non-small-cell lung cancer treatment (r)evolution: ten years of advances and more to come. Ecancermedicalscience 11, 787 (2017). - PMC - PubMed
    1. Addeo A, Banna GL, Metro G, Di Maio M. Chemotherapy in combination with immune checkpoint inhibitors for the first-line treatment of patients with advanced non-small-cell lung cancer: a systematic review and literature-based meta-analysis. Front. Oncol. 9, 264 (2019). - PMC - PubMed
    1. Reck M, Rodríguez-Abreu D, Robinson AG. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375(19), 1823–1833 (2016). - PubMed
    1. Spigel D, de Marinis F, Giaccone G. et al. Impower110: interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1-selected NSCLC. Ann. Oncol. 30(Suppl. 5), v851–v934 (2019).
    1. Brahmer JR, Drake CG, Wollner I. et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28(19), 3167–3175 (2010). - PMC - PubMed

Publication types

LinkOut - more resources